Drug Trial Radar · NCT05904691
Safety and Tolerability of OCU-10-C-110 for Injection in Subjects With Neovascular Age-related Macular Degeneration
Last checked: Nov 20, 2026Latest source record: May 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
24
Actual
Start
Nov 1, 2023
Primary completion
Nov 30, 2026
Study completion Nov 30, 2026
Sponsor
- Lead sponsor
- Ocugenix CorporationIndustry
- Sponsor type
- Industry
- First posted
- Jun 15, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Multi-center, open-label, two-part safety assessment following administration of single ascending doses and repeat administration of the HTD of OCU-10-C-110 for Injection in the study eye of participants with nAMD
Conditions
- Neovascular Age-related Macular Degeneration (nAMD)
Interventions
OCU-10-C-110 for InjectionDrug
OCU-10-C-110 for Injection in one of 3 doses
Primary outcomes
What the sponsor says the trial is designed to measure.
- Ocular safety - AETime frame: Cohort A - 8 weeks; Cohort B - 12 weeks
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Raj K. Maturi, M.D., P.C.
Carmel, Indiana
Retina Research Institute of Texas
Abilene, Texas
Strategic Clinical Research Group LLC
Willow Park, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.